Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Insider grant and holdings update: Darren Sherman, listed as a director and as President and Chief Operating Officer of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 120,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the award was reported as acquired at a $0 price.
The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continued service. Following the reported transaction, the filing shows 923,837 shares beneficially owned by the reporting person in a direct ownership form.
Orchestra BioMed Holdings (OBIO) director Pamela Ann Connealy was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition is recorded at a $0 price.
The RSUs are scheduled to vest on the one‑year anniversary of the grant date, subject to the reporting persons continuous service through that date. Following the award, Ms. Connealy beneficially owns 48,711 shares of common stock, held directly.
The filing lists Ms. Connealys relationship to the issuer as a director. No derivative securities or dispositions are reported in this Form 4.
Orchestra BioMed Holdings director Mack John Prosper was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a per-unit price of $0. The RSUs are scheduled to vest on the one-year anniversary of the grant, subject to the reporting persons continuous service through that date. After this award the reporting person beneficially owns 40,286 shares on a direct basis.
The Form 4 shows the transaction as an acquisition (code A) and was filed by one reporting person. No derivative securities or additional transactions are reported in this filing and no other material details are provided.
Orchestra BioMed director Eric S. Fain was awarded 7,500 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a transaction price of $0. The RSUs will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date.
The Form 4 reports that following the reported acquisition the Reporting Person beneficially owns 7,500 shares directly and 58,449 shares indirectly through the Fain Living Trust. The filing discloses the RSU grant as the non-derivative acquisition reported on the form.
Orchestra BioMed Holdings, Inc. (OBIO) filed a Form 4 reporting that director Chris Cleary was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the grant is recorded with a price of $0 in the filing. The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the reporting persons continuous service through that date.
The transaction is shown as an acquisition and, after the award, Mr. Cleary beneficially owns 37,577 shares on a direct basis. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on 08/08/2025.
Orchestra BioMed Holdings reported that Director and CEO David P. Hochman was awarded 100,000 restricted stock units (RSUs) on 08/07/2025, each representing a contingent right to one share of common stock. After the award, Mr. Hochman's reported direct beneficial ownership is 645,460 shares; indirect holdings include 449,331 shares held by the DPH 2008 Trust and smaller trust holdings of 2,000, 2,000, 2,000 and 3,140 shares. The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continuous service. The filing identifies Mr. Hochman as Chief Executive Officer and Chairperson.
Orchestra BioMed director David Pacitti was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the RSUs vest on the one-year anniversary of the grant, subject to the reporting person's continuous service through that date.
Following the award, the reporting person beneficially owns 44,968 shares of common stock in a direct ownership form. The RSUs carry no stated cash price and will convert to shares upon vesting.
Joshua Aiello, Principal Accounting Officer at Orchestra BioMed Holdings, Inc. (OBIO), reported an award of 15,000 restricted stock units (RSUs) on August 7, 2025. Each RSU represents a contingent right to one share of common stock and the grant lists a $0 per-share price. The RSUs vest in three tranches over three years: 33.33% vest 24 months after the grant date, 33.33% vest 30 months after the grant date, and 33.34% vest 36 months after the grant date, subject to continuous service. The Form 4 shows 19,329 shares as beneficially owned following the reported transaction and is signed by an attorney-in-fact on August 8, 2025.
RTW Investments, LP and affiliated funds ("RTW") filed Amendment No. 5 to Schedule 13D on Orchestra BioMed Holdings, Inc. (OBIO) dated 08 Aug 2025. The amendment reflects RTW’s 04 Aug 2025 purchase of 3,636,363 pre-funded warrants at $2.7499 each (total $9.999 million) in the company’s August 2025 public offering. The warrants carry a de-minimis exercise price of $0.0001 but are subject to a 9.99 % ownership cap (adjustable up to 19.99 % after 61 days), so the underlying shares are not presently deemed beneficially owned.
After the transaction RTW reports 8,306,063 common shares, equating to 15.4 % of OBIO’s 53,952,798 outstanding shares. Break-down: RTW Master Fund 4.395 M (8.1 %), RTW Innovation Master Fund 3.053 M (5.7 %), RTW Biotech Fund 0.858 M (1.6 %). Dr. Roderick Wong, Managing Partner, is the controlling individual and is deemed to share voting and dispositive power over all reported shares.
Key investor takeaways: RTW remains OBIO’s largest known shareholder, injected ~$10 M fresh capital, and holds additional warrant optionality that could increase its stake and dilute existing holders once exercise restrictions lapse.
On 08/04/2025, RTW Investments, LP—together with Managing Partner Dr. Roderick Wong—filed a Form 4 disclosing the purchase of 3,636,363 pre-funded warrants in Orchestra BioMed Holdings (OBIO). The warrants were acquired at $2.7499 per warrant (Transaction Code “P”) and carry a nominal exercise price of $0.0001 per share. Each warrant is immediately exercisable into one common share, but exercise is limited so total beneficial ownership does not exceed 9.99 % of OBIO’s outstanding stock.
The filing confirms RTW and Dr. Wong as >10 % shareholders and directors. Post-transaction, they hold 3.64 million derivative securities that, if fully exercised, could add an equivalent number of common shares to OBIO’s float, creating potential dilution. The warrants have no expiration date, giving the insiders flexibility on timing.